z-logo
Premium
Effect of N G ‐monomethyl‐L‐arginine on kinin‐induced vasodilation in the human forearm.
Author(s) -
Cockcroft JR,
Chowienczyk PJ,
Brett SE,
Ritter JM
Publication year - 1994
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1994.tb04358.x
Subject(s) - bradykinin , vasodilation , forearm , brachial artery , endocrinology , omega n methylarginine , substance p , medicine , kinin , chemistry , blood pressure , neuropeptide , nitric oxide synthase , nitric oxide , anatomy , receptor
1. We compared effects of NG‐monomethyl‐L‐arginine (L‐NMMA), an NO synthase inhibitor, on vasodilator responses to intra‐arterial infusion of bradykinin and substance P in the human forearm. 2. Bradykinin (100 pmol min‐1) increased forearm blood flow when infused into the brachial artery of eight healthy male volunteers, from 2.8 +/‐ 0.2 (mean +/‐ s.e. mean) to 9.3 +/‐ 1.0 ml min‐1 per 100 ml forearm volume. 3. Co‐ infusion of L‐NMMA (2 mumol min‐1 and 4 mumol min‐1) with bradykinin (100 pmol min‐1) for 6 min produced respectively a 9 +/‐ 14% and 42 +/‐ 14% inhibition (compared with L‐NMMA vehicle) in the response to bradykinin. 4. Substance P (1 pmol min‐1) when infused into the brachial artery of a further eight male subjects increased forearm blood flow from 3.4 +/‐ 0.2 to 6.3 +/‐ 0.7 ml min‐1 100 ml‐1. 5. Co‐ infusion of L‐NMMA (2 mumol min‐1 and 4 mumol min‐1) with substance P (1 pmol min‐1) for 6 min produced respectively a 27 +/‐ 8% and 70 +/‐ 13% inhibition (compared with L‐NMMA vehicle) in the response to substance P. 6. These results demonstrate that vasodilator responses to both bradykinin and substance P are mediated in part via the L‐ arginine/NO pathway. Bradykinin and substance P may be useful agonists with which to study endothelial function in this vascular bed.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here